The FDA’s approval of Ozempic to battle chronic kidney disease “allows us to more broadly address conditions within cardiovascular-kidney-metabolic syndrome, which affects millions of ...
Vertex Pharmaceuticals won FDA approval for its non-opioid painkiller Journavx. Vertex stock jumped in late trading.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback